Final efficacy and biomarker analysis of the sorafenib arm of the BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) trial
Homo sapiens
37 Downloadable Samples
Affymetrix Human Gene 1.0 ST Array (hugene10st)
Submitter Supplied Information
Description
Purpose: To determine the 8-week disease control rate (DCR) of sorafenib monotherapy in patients with advanced non-small-cell lung cancer (NSCLC) in the BATTLE trial.